Payment overview · 2025
General Payments
$4,051.27
7 reported records · 5 companies
Healthcare provider profile · identity verified
Marina Basina, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism · STANFORD, CA · NPI 1023196805
Verified facts
What the public records show
CMS Open Payments records show Marina Basina, MD received $4,051.27 in general payments during 2025 across 7 reported records.
SANOFI-AVENTIS U.S. LLC accounted for 85.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $3,480.30 | 85.9% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $153.40 | 3.8% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$147.45 | 3.6% | 1 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $144.73 | 3.6% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $125.39 | 3.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $3,228.90 | 1 |
| Food and Beverage | $822.37 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $153.40 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $147.45 | 1 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $144.73 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $125.39 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $107.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 580 | 148 |
| Mounjaro | Tirzepatide | 471 | 84 |
| Metformin Hcl | Metformin Hcl | 467 | 137 |
| Ozempic | Semaglutide | 397 | 90 |
| Jardiance | Empagliflozin | 355 | 104 |
| Trulicity | Dulaglutide | 329 | 75 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 307 | 130 |
| Metformin Hcl Er | Metformin Hcl | 243 | 62 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 200 | 82 |
| Glipizide | Glipizide | 195 | 58 |
| Humalog Kwikpen U-100 | Insulin Lispro | 159 | 62 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 139 | 34 |
| Atorvastatin Calcium | Atorvastatin Calcium | 138 | 42 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 134 | 48 |
| Tresiba Flextouch U-200 | Insulin Degludec | 123 | 30 |
| Repaglinide | Repaglinide | 119 | 33 |
| Tresiba Flextouch U-100 | Insulin Degludec | 115 | 43 |
| Synthroid | Levothyroxine Sodium | 105 | 27 |
| Januvia | Sitagliptin Phosphate | 101 | 32 |
| Insulin Aspart Flexpen | Insulin Aspart | 93 | 28 |
| Novolog Flexpen | Insulin Aspart | 92 | 40 |
| Rybelsus | Semaglutide | 86 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 82 | 18 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 81 | 35 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 76 | 21 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 74 | 25 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 73 | 32 |
| Alendronate Sodium | Alendronate Sodium | 71 | 21 |
| Glipizide Er | Glipizide | 68 | 25 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 61 | 15 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 59 | 14 |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 58 | 18 |
| Humalog | Insulin Lispro | 55 | 21 |
| Hydrocortisone | Hydrocortisone | 55 | 11 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 53 | 11 |
| Losartan Potassium | Losartan Potassium | 52 | 17 |
| Methimazole | Methimazole | 50 | 14 |
| Farxiga | Dapagliflozin Propanediol | 45 | 12 |
| Tradjenta | Linagliptin | 45 | 15 |
| Novolog | Insulin Aspart | 44 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 41 | 13 |
| Creon | Lipase/Protease/Amylase | 40 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 40 | 11 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 36 | 17 |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 32 | 12 |
| Droplet Pen Needle | Pen Needle, Diabetic | 31 | 13 |
| Glimepiride | Glimepiride | 31 | suppressed |
| Tymlos | Abaloparatide | 31 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 30 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 27 | suppressed |
| Lisinopril | Lisinopril | 27 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 26 | suppressed |
| Gabapentin | Gabapentin | 26 | 11 |
| Prednisone | Prednisone | 26 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 25 | suppressed |
| Simvastatin | Simvastatin | 25 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 24 | suppressed |
| Gvoke Hypopen 2-Pack | Glucagon | 23 | suppressed |
| Baqsimi | Glucagon | 22 | 14 |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 22 | suppressed |
| Insulin Aspart | Insulin Aspart | 22 | suppressed |
| Insulin Lispro | Insulin Lispro | 22 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 20 | suppressed |
| Teriparatide | Teriparatide | 18 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 17 | suppressed |
| Acarbose | Acarbose | 16 | suppressed |
| Omeprazole | Omeprazole | 16 | suppressed |
| Ezetimibe | Ezetimibe | 15 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 15 | suppressed |
| Invokana | Canagliflozin | 15 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Omnipod Dash Pods (Gen 4) | Insulin Pump Cart,cont Inf,bt | 15 | suppressed |
| Victoza 3-Pak | Liraglutide | 15 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 13 | suppressed |
| Humalog Mix 50-50 Kwikpen | Insulin Lispro Protamin/Lispro | 13 | suppressed |
| Testosterone | Testosterone | 13 | suppressed |
| Ultra-Fine Original Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Insulin Aspart Prot Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 12 | suppressed |
| Omnipod 5 Dexg7g6 Intro(Gen 5) | Insulin Pmp Cart,aut,g6/7,cntr | 12 | 12 |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Praluent Pen | Alirocumab | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,051.27 · 7 records | SANOFI-AVENTIS U.S. LLC | Dexcom G6 Transmitter, Korlym, MINIMED 780G, TWIIST, TZIELD | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with SANOFI-AVENTIS U.S. LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error